Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B
P Marcellin, EJ Heathcote, M Buti, E Gane… - … England Journal of …, 2008 - Mass Medical Soc
Background Tenofovir disoproxil fumarate (DF) is a nucleotide analogue and a potent
inhibitor of human immunodeficiency virus type 1 reverse transcriptase and hepatitis B virus …
inhibitor of human immunodeficiency virus type 1 reverse transcriptase and hepatitis B virus …
[PDF][PDF] Long‐term efficacy of tenofovir monotherapy for hepatitis B virus‐monoinfected patients after failure of nucleoside/nucleotide analogues
F van Bömmel, RA de Man, H Wedemeyer… - …, 2010 - Wiley Online Library
Tenofovir disoproxil fumarate (TDF) has demonstrated high antiviral efficacy in treatment‐
naive patients with chronic hepatitis B virus (HBV) infection but experience in …
naive patients with chronic hepatitis B virus (HBV) infection but experience in …
Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B
EJ Heathcote, P Marcellin, M Buti, E Gane, A Robert… - Gastroenterology, 2011 - Elsevier
BACKGROUND & AIMS: Tenofovir disoproxil fumarate (TDF), a nucleotide analogue and
potent inhibitor of hepatitis B virus (HBV) polymerase, showed superior efficacy to adefovir …
potent inhibitor of hepatitis B virus (HBV) polymerase, showed superior efficacy to adefovir …
Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in virologically suppressed patients with chronic hepatitis B: a randomised, double-blind, phase 3 …
P Lampertico, M Buti, S Fung, SH Ahn… - The lancet …, 2020 - thelancet.com
Background Treatment with tenofovir disoproxil fumarate has been associated with renal
toxicity or reductions in bone mineral density, or both, in some patients with chronic hepatitis …
toxicity or reductions in bone mineral density, or both, in some patients with chronic hepatitis …
Ten‐year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B virus infection
P Marcellin, DK Wong, W Sievert, P Buggisch… - Liver …, 2019 - Wiley Online Library
Abstract Background & Aims Tenofovir disoproxil fumarate (TDF) is a first‐line treatment for
chronic hepatitis B (CHB). We aimed to describe the efficacy and safety profiles of TDF …
chronic hepatitis B (CHB). We aimed to describe the efficacy and safety profiles of TDF …
96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection
Background & Aims Tenofovir alafenamide (TAF) is a new prodrug of tenofovir developed to
treat patients with chronic hepatitis B virus (HBV) infection at a lower dose than tenofovir …
treat patients with chronic hepatitis B virus (HBV) infection at a lower dose than tenofovir …
Twenty-eight day safety, antiviral activity, and pharmacokinetics of tenofovir alafenamide for treatment of chronic hepatitis B infection
K Agarwal, SK Fung, TT Nguyen, W Cheng, E Sicard… - Journal of …, 2015 - Elsevier
Background & Aims Tenofovir alafenamide, a phosphonate prodrug of tenofovir with greater
plasma stability than tenofovir disoproxil fumarate, provides efficient delivery of active drug …
plasma stability than tenofovir disoproxil fumarate, provides efficient delivery of active drug …
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3 …
Background Tenofovir alafenamide is a novel prodrug formulated to deliver the active
metabolite to target cells more efficiently than tenofovir disoproxil fumarate at a lower dose …
metabolite to target cells more efficiently than tenofovir disoproxil fumarate at a lower dose …
Effectiveness and safety of tenofovir disoproxil fumarate in chronic hepatitis B: a 3-year, prospective, real-world study in France
P Marcellin, F Zoulim, C Hézode, X Causse… - Digestive diseases and …, 2016 - Springer
Abstract Background and Aims Tenofovir disoproxil fumarate (TDF) demonstrated potent
and sustainable antiviral efficacy and a good safety profile in patients with chronic hepatitis …
and sustainable antiviral efficacy and a good safety profile in patients with chronic hepatitis …
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double …
Background The novel prodrug tenofovir alafenamide delivers the nucleotide reverse
transcriptase inhibitor tenofovir to target cells more efficiently at a lower dose than tenofovir …
transcriptase inhibitor tenofovir to target cells more efficiently at a lower dose than tenofovir …